MPN Landmark Survey Reveals Insights About Living With MPNs
Living with a rare disease such as a myeloproliferative neoplasm (MPN) can be isolating. You might expect that friends, family, or coworkers may not understand the day-to-day challenges of living with an MPN. Did you know, however, that a survey of patients with MPNs and Healthcare Professionals (HCPs) revealed gaps in the way patients and HCPs view the MPN patient experience?
What is the MPN Landmark Survey?
The MPN Landmark Survey, sponsored by Incyte Corporation, is a large-scale analysis of patients with myeloproliferative neoplasms (MPNs) and HCPs who treat these rare, chronic blood cancers. The survey assessed patients' perceptions of their overall disease burden, quality of life, activities of daily living, and work productivity.
The survey focused on the three "classic" MPNs―myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). A total of 813 patients in the US diagnosed with MF, PV, or ET completed the survey (207 with MF; 380 with PV; and 226 with ET).
What were the MPN Landmark Survey results?
The MPN Landmark Survey was conducted to understand the gaps between patient and HCP perceptions about patient disease management. It was also designed to help identify areas in which patients and HCPs could improve their interactions. The survey findings also highlight the impact that MPN symptoms may have on quality of life, everyday activities, and work productivity. The results from the study provide new information that validates previous findings about the effects of MPNs. It’s important to explore the differences in perception reported in the survey between patients and HCPs to advance the understanding and treatment of MPNs.
See select findings from the MPN Landmark Survey in the videos below.
If you or a loved one are living with an MPN, the following additional resources may help you better communicate with your HCP about the impact your MPN has on you. Taking the initiative to clearly communicate with your HCP may help you better understand your disease and encourage you to take a more active role in your care.
*The MPN Landmark Survey was funded by Incyte Corporation.